4.35
price down icon6.25%   -0.29
after-market Dopo l'orario di chiusura: 4.41 0.06 +1.38%
loading
Precedente Chiudi:
$4.64
Aprire:
$4.6
Volume 24 ore:
3.61M
Relative Volume:
1.05
Capitalizzazione di mercato:
$585.06M
Reddito:
-
Utile/perdita netta:
$-217.44M
Rapporto P/E:
-2.0046
EPS:
-2.17
Flusso di cassa netto:
$-205.20M
1 W Prestazione:
+11.54%
1M Prestazione:
+76.83%
6M Prestazione:
+38.10%
1 anno Prestazione:
-20.77%
Intervallo 1D:
Value
$4.235
$4.67
Intervallo di 1 settimana:
Value
$3.90
$5.17
Portata 52W:
Value
$1.11
$5.9499

Prime Medicine Inc Stock (PRME) Company Profile

Name
Nome
Prime Medicine Inc
Name
Telefono
617-465-0013
Name
Indirizzo
60 FIRST ST., CAMBRIDGE
Name
Dipendente
214
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
PRME's Discussions on Twitter

Confronta PRME con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PRME
Prime Medicine Inc
4.35 609.27M 0 -217.44M -205.20M -2.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Prime Medicine Inc Stock (PRME) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-27 Downgrade Citigroup Buy → Neutral
2025-05-20 Downgrade H.C. Wainwright Buy → Neutral
2025-05-20 Downgrade JP Morgan Overweight → Neutral
2024-12-10 Iniziato JMP Securities Mkt Outperform
2024-05-20 Iniziato H.C. Wainwright Buy
2024-05-16 Aggiornamento Citigroup Neutral → Buy
2024-04-22 Iniziato Chardan Capital Markets Buy
2024-04-08 Iniziato TD Cowen Buy
2024-04-03 Iniziato Wedbush Outperform
2024-01-16 Downgrade Stifel Buy → Hold
2023-12-08 Iniziato Citigroup Neutral
2023-10-09 Iniziato BMO Capital Markets Outperform
2023-07-31 Iniziato Guggenheim Buy
2023-04-18 Iniziato Stifel Buy
2022-11-14 Iniziato Goldman Neutral
2022-11-14 Iniziato JP Morgan Overweight
2022-11-14 Iniziato Jefferies Buy
2022-11-14 Iniziato Morgan Stanley Equal-Weight
Mostra tutto

Prime Medicine Inc Borsa (PRME) Ultime notizie

pulisher
Jul 24, 2025

Is Prime Medicine Inc. stock a good hedge against inflationFree Risk Assessment Services - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

Is Prime Medicine Inc. a good long term investmentMassive profits - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Prime Medicine Inc. stockAccelerated investment success - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Prime Medicine Inc. Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

What drives Prime Medicine Inc. stock priceExponential wealth increase - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Prime Medicine(PRME) Shares Soar 10.65% on Analyst Rating, Funding Boost - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Prime Medicine Surges 18% on Funding Catalyst: Is This the Start of a Biotech Breakout? - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT - MSN

Jul 21, 2025
pulisher
Jul 21, 2025

Prime Medicine stock price target reiterated at $6 by JMP on CF funding - Investing.com Canada

Jul 21, 2025
pulisher
Jul 20, 2025

Prime Medicine (PRME.O) Surges 5.9%: What’s Behind the Intraday Rally? - AInvest

Jul 20, 2025
pulisher
Jul 20, 2025

Prime Medicine (PRME): A High-Conviction Biotech Play with a 154% Upside - AInvest

Jul 20, 2025
pulisher
Jul 18, 2025

10 Hot Penny Stocks to Invest in Now - Insider Monkey

Jul 18, 2025
pulisher
Jul 17, 2025

Cystic Fibrosis Foundation grants new funding to advance development of Prime Medicine’s prime editors - BioWorld MedTech

Jul 17, 2025
pulisher
Jul 17, 2025

Prime Medicine, Inc.: Buy Rating Affirmed on Innovative Gene Editing Technology and Strategic Advancements - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Prime Medicine stock rating reiterated by H.C. Wainwright on CF partnership - Investing.com Canada

Jul 17, 2025
pulisher
Jul 16, 2025

CF Trading Volume Surges 77% to 2.91 Billion, Ranks 364th in Market - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Prime Medicine Announces CSO Resignation and Transition - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Prime Editing's Billion-Dollar Gamble: Can Prime Medicine's $24M Boost Cement Dominance in Cystic Fibrosis? - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Prime Medicine announces additional funding of up to $24M from CF Foundation - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

Prime Medicine Announces Additional Funding of Up to $24 - GlobeNewswire

Jul 16, 2025
pulisher
Jul 16, 2025

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation - citybiz

Jul 16, 2025
pulisher
Jul 16, 2025

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis - The Manila Times

Jul 16, 2025
pulisher
Jul 16, 2025

Cystic Fibrosis Foundation expands funding for Prime Medicine By Investing.com - Investing.com Nigeria

Jul 16, 2025
pulisher
Jul 16, 2025

Prime Medicine Secures Up to $24 Million from Cystic Fibrosis Foundation to Advance Prime Editing Technology for Cystic Fibrosis Treatment - Nasdaq

Jul 16, 2025
pulisher
Jul 16, 2025

Cystic Fibrosis Foundation expands funding for Prime Medicine - Investing.com

Jul 16, 2025
pulisher
Jul 16, 2025

CF Foundation Backs Prime Medicine with $24M to Develop Cure for 93% of Cystic Fibrosis Patients - Stock Titan

Jul 16, 2025
pulisher
Jul 15, 2025

Prime Medicine chief scientific officer to depart, will serve as consultant - Investing.com Nigeria

Jul 15, 2025
pulisher
Jul 11, 2025

Prime Medicine, Inc. shares rise 2.99% premarket after Fifty1 AI Labs' successful completion of the REVIVE Clinical Trial. - AInvest

Jul 11, 2025

Prime Medicine Inc Azioni (PRME) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):